Welcome to our dedicated page for Petvivo Hldgs SEC filings (Ticker: PETV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PetVivo Holdings, Inc. (PETV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nevada corporation with Commission File Number 001-40715, PetVivo submits current reports, periodic reports and exhibits that document material events, governance changes, financing transactions and investor communications related to its animal health and veterinary AI businesses.
For PetVivo, Form 8-K current reports are particularly relevant. Recent 8-K filings have covered topics such as the appointment and resignation of directors, changes in board size, entry into note conversion agreements with shareholders, and the furnishing of investor presentations under Regulation FD. These filings can give investors insight into PetVivo’s corporate governance, capital structure adjustments and how it communicates its strategy around products like SPRYNG with OsteoCushion technology, PrecisePRP and the PetVivo.ai platform.
In addition to current reports, investors may consult PetVivo’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for detailed information on business operations, risk factors, financial statements and segment discussions related to its veterinary medical devices, regenerative products and AI initiatives. Form 4 and other ownership filings, when filed, can be used to monitor equity transactions by directors, officers and significant shareholders.
Stock Titan enhances these filings with AI-powered summaries that explain key points in clear language, helping readers interpret complex disclosures such as note conversions, licensing agreements or board changes. Real-time updates from EDGAR ensure that new PETV filings appear promptly, while structured access to exhibits like investor presentations allows users to review the same materials referenced in PetVivo’s Regulation FD communications.
PetVivo Holdings, Inc. entered into a Subscription Agreement for $1,000,000 of equity financing through 1,250,000 units priced at $0.80 per unit. Each unit includes one restricted common share and a warrant to buy one share at $1.10, exercisable immediately and expiring three years from issuance.
The company received $400,000 on March 13, 2026 and expects the remaining $600,000 by April 15, 2026. The investor also received an option to provide an additional $1,500,000 for 1,875,000 more units on the same terms, anticipated by June 30, 2026. The private placement was conducted under Section 4(a)(2) and Regulation D, with the investor representing accredited status, and all securities issued as restricted under Rule 144.
PetVivo Holdings, Inc. disclosed that A.L. Sarroff Fund, LLC, a ten percent owner, made open-market purchases of its common stock. The fund bought a total of 24,033 shares on March 23, 2026, including 23,033 shares at $0.68 and 1,000 shares at $0.7499 per share. Following these transactions, the fund directly holds 10,202,229 common shares, with Alan L. Sarroff deemed to beneficially own and exercise sole voting and dispositive power over these securities.
Rudelius Robert James reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. director Robert James Rudelius received a one-time grant of 35,000 shares of restricted common stock as compensation for prior Board service, valued at $0.74 per share on the grant date. Following this award, he directly holds 353,392 common shares. He also has an additional 21,000 shares reported as indirectly held through a corporation. This Form 4 reflects a compensation-related share grant rather than an open-market purchase or sale.
Ruben Joshua David reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings director Ruben Joshua David reported stock-based compensation grants. He received an aggregate annual grant of 46,332 restricted common shares for Board service, vesting in four installments: 8,832 shares for the pro-rated first quarter and 12,500 shares at the beginning of each subsequent quarter of service.
He also received a one-time grant of 7,500 restricted shares as compensation for prior Board service. Following these awards, he holds 53,832 common shares directly. These are compensation-related grants, not open-market purchases or sales.
PetVivo Holdings, Inc. director Diane M. Levitan reported an acquisition of 15,000 shares of common stock at $0.74 per share. The transaction is coded as a grant or award, meaning these shares were received as compensation rather than bought in the open market.
According to a footnote, this is a one-time grant of 15,000 restricted common shares as compensation for prior Board service. Following this award, Levitan directly owns 71,489 shares of PetVivo common stock.
Jasper Joseph William reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. director Jasper Joseph William received a one-time grant of 35,000 shares of restricted common stock as compensation for prior Board service, valued at $0.74 per share on the grant date. Following this award, he directly holds 135,159 common shares, with an additional 2,000 shares held indirectly by his wife. This is a compensation-related equity grant, not an open-market purchase.
Costantino Robert J reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. reported that director Robert J. Costantino received a one-time grant of 35,000 shares of restricted common stock as compensation for prior Board service. The grant, valued at $0.74 per share for reporting purposes, increases his direct holdings to 108,661 shares of common stock.
PetVivo Holdings, Inc. entered into a Subscription Agreement to receive $1,000,000 of equity financing in exchange for 1,250,000 shares of restricted common stock. The company received an initial $400,000 on March 13, 2026 and expects the remaining $600,000 on or before April 15, 2026.
The investor also received a purchase option to invest an additional $1,500,000 for 1,875,000 restricted shares, anticipated on or before June 30, 2026, on the same terms. The transaction is a private offering to an accredited investor under Section 4(a)(2) and Regulation D, and the shares are restricted securities subject to Rule 144.
A.L. Sarroff Fund, LLC, a 10% owner of PetVivo Holdings, Inc., reported open-market purchases tied to a unit financing. The fund acquired 1,250,000 Warrants to buy Common Stock with an exercise price of $1.10 per share, expiring on March 13, 2029.
According to the footnotes, these Warrants and 1,250,000 shares of Common Stock were purchased as Units at $0.80 per Unit, with each Unit consisting of one share and one Warrant. Following the stock purchase, the fund holds 10,178,196 Common shares directly.
PetVivo Holdings, Inc. received a significant investment from A.L. Sarroff Fund, LLC, Alan Sarroff, and Eileen Sarroff, who now report beneficial ownership of 16,433,204 shares of common stock, or about 39.6% of the company, including assumed exercise of warrants.
On March 13, 2026, these investors agreed to purchase 1,250,000 units in a private placement at $0.80 per unit, with each unit consisting of one common share and a warrant to buy one additional share at $1.10. They also obtained an option, exercisable until June 15, 2026, to purchase up to 1,500,000 more units at the same price.
The investors describe their stake as for investment purposes but state they may increase or decrease their holdings over time, including through additional securities or derivatives tied to PetVivo’s stock. They also note the possibility of entering into swaps, options, or other derivative transactions that could be significant in size.